Promotions & Moves

Perrigo Names New CEO

Röhrhoff succeeds John T. Hendrickson

By: Kristin Brooks

Managing Editor, Contract Pharma

Uwe Röhrhoff has been appointed president and chief executive officer, Perrigo Company, effective January 15, 2018, following the retirement of John T. Hendrickson.
 
Mr. Röhrhoff has more than 25 years of experience with Gerresheimer AG, a global manufacturer of pharmaceutical packaging products and medical devices for storage, dosage and administration of drugs. He began his career with Gerresheimer AG in 1991, advancing to serve in a number of key leadership roles in Europe and North America. Mr. Röhrhoff was appointed to build out the company’s business in the U.S. (1996-1998) and head the American subsidiary Gerresheimer Glass Inc. (2001-2010). He served as an executive board member (2003-2017), responsible for two of the company’s three business units, and chief executive officer (2010-2017) of Gerresheimer AG.
 
Mr. Hendrickson will resign as chief executive officer and board member on January 15, 2018 and will remain with the company until March 15, 2018 to ensure a smooth transition.

Perrigo Chairman Laurie Brlas said, “The Board of Directors is excited to announce the appointment of Uwe. Uwe brings a strong track record of operational excellence, strategic growth, and healthcare supply chain management. As the CEO of Gerresheimer AG, a publicly-traded international manufacturer for the global pharmaceutical and healthcare industries, Uwe’s transformative strategic vision and focus on operational excellence enhanced the company’s leading market positions and created significant value for shareholders of approximately 225% in total shareholder return as CEO. We are confident that his leadership style and industry, financial and operational expertise are the right fit for Perrigo. We are grateful to John for his passionate leadership and contributions to the Company over the past 28 years. John has been a trusted leader, a great colleague, and a friend to many, and we value his continued guidance as Uwe transitions into his new role.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters